Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $0.09.

  • BeOne Medicines' EPS (Basic) rose 20000.0% to $0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.05, marking a year-over-year increase of 10781.25%. This contributed to the annual value of -$0.47 for FY2024, which is 2769.23% up from last year.
  • Latest data reveals that BeOne Medicines reported EPS (Basic) of $0.09 as of Q3 2025, which was up 20000.0% from $0.07 recorded in Q2 2025.
  • BeOne Medicines' EPS (Basic)'s 5-year high stood at $0.16 during Q3 2023, with a 5-year trough of -$0.49 in Q4 2021.
  • For the 5-year period, BeOne Medicines' EPS (Basic) averaged around -$0.19, with its median value being -$0.26 (2023).
  • As far as peak fluctuations go, BeOne Medicines' EPS (Basic) crashed by 65000.0% in 2022, and later surged by 20000.0% in 2025.
  • Over the past 5 years, BeOne Medicines' EPS (Basic) (Quarter) stood at -$0.49 in 2021, then soared by 32.65% to -$0.33 in 2022, then increased by 18.18% to -$0.27 in 2023, then skyrocketed by 59.26% to -$0.11 in 2024, then skyrocketed by 181.82% to $0.09 in 2025.
  • Its last three reported values are $0.09 in Q3 2025, $0.07 for Q2 2025, and $0.0 during Q1 2025.